|
1
|
Rudnicka L, Chrostowska S, Kamiński M,
Waśkiel-Burnat A, Michalczyk A, Rakowska A and Olszewska M: The
role of trichoscopy beyond hair and scalp diseases. A review. J Eur
Acad Dermatol Venereol: Mar 15, 2023 (Epub ahead of print).
|
|
2
|
Michael A, Fuller T, Brogan S and Murphy
MC: An intrathecal pump misadventure in two acts: An unrecognized
partial pocket fill followed by an unusual withdrawal syndrome two
months later. J Palliat Med: Jan 30, 2025 (Epub ahead of
print).
|
|
3
|
Chang YC, Peng CY, Chi KY, Song J, Chang Y
and Chiang CH, Gao W and Chiang CH: Cardiovascular outcomes and
mortality in diabetic multiple myeloma patients initiated on
proteasome inhibitors according to prior use of glucagon-like
peptide 1 agonists. Eur J Prev Cardiol: Jan 29, 2025 (Epub ahead of
print).
|
|
4
|
Jia J, Yin J, Geng C and Liu A:
Characteristics and outcomes of secondary acute lymphoblastic
leukemia (sALL) after multiple myeloma (MM): SEER data analysis in
a single-center institution. Cancer Pathog Ther. 3:76–80.
2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Rapparini L, Pileri A, Robuffo S,
Agostinelli C and La Placa M: Cutaneous involvement in multiple
myeloma. A rare entity. Clin Case Rep. 13(e9476)2025.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Růžičková T, Vlachová M, Pečinka L,
Brychtová M, Večeřa M, Radová L and Ševčíková S, Jarošová M, Havel
J, Pour L and Ševčíková S: Detection of early relapse in multiple
myeloma patients. Cell Div. 20(4)2025.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yang J, Hu Q, Lu J, Wang J, Wu D, Fei X,
Wang L, Yu X and Tang Y: DRESS is not a rare complication during
the initial treatment of newly diagnosed multiple myeloma: The
experience of two medical institutes. Acta Haematol: Jan 27, 2025
(Epub ahead of print).
|
|
8
|
Wildes TM: First relapse in older adults
with multiple myeloma: Creating new pathways in uncharted
territory. Br J Haematol. 206:1523–1525. 2025.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Xue W, Li Y, Ma Y and Zhang F:
GDF15-mediated enhancement of the Warburg effect sustains multiple
myeloma growth via TGFβ signaling pathway. Cancer Metab.
13(3)2025.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sampath VS: Isatuximab-based therapy for
multiple myeloma. N Engl J Med. 392:518–519. 2025.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Oymanns M, Baltaci M, Bellm A and Assaf C:
Paraneoplastic filiform hyperkeratosis and
immunoglobulin-associated vasculitis in myeloma progression: A case
report. Case Rep Dermatol. 13:563–567. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z,
Jin L, Xia J, Ma S, Liu Y, et al: Long-term follow-up of
combination of B-cell maturation antigen and CD19 chimeric antigen
receptor T cells in multiple myeloma. J Clin Oncol. 40:2246–2256.
2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Mettias S, ElSayed A, Moore J and Berenson
JR: Multiple myeloma: Improved outcomes resulting from a rapidly
expanding number of therapeutic options. Target Oncol. 20:247–267.
2025.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Liehr T: International system for human
cytogenetic or cytogenomic nomenclature (ISCN): Some thoughts.
Cytogenet Genome Res. 161:223–224. 2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Giorgetti G, Maroto-Martin E, Soncini D,
Fenoglio D, Becherini P, Benzi A, Ravera S, Traverso I, Ladisa F,
Lai F, et al: CD56 expression modulates NAD+ metabolic landscape
and predicts sensitivity to anti-CD38 therapies in multiple
myeloma. Blood Cancer J. 15(83)2025.PubMed/NCBI View Article : Google Scholar
|
|
16
|
L B Andrade C, Ferreira MV, M Alencar B, S
B Filho JL, A Guimaraes M, Porto Cruz Moraes I, S Lopes TJ, S Dos
Santos A, M Dos Santos M, C S E Silva MI, et al: PCMMD: A novel
dataset of plasma cells to support the diagnosis of multiple
myeloma. Sci Data. 12(161)2025.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Penfield JG: Multiple myeloma in end-stage
renal disease. Semin Dial. 19:329–334. 2006.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Bou Zerdan M, Nasr L, Khalid F, Allam S,
Bouferraa Y, Batool S, Tayyeb M, Adroja S, Mammadii M, Anwer F, et
al: Systemic AL amyloidosis: current approach and future direction.
Oncotarget. 14:384–394. 2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Jhaveri KD, Meena P, Bharati J and Bathini
S: Recent updates in the diagnosis and management of kidney
diseases in multiple myeloma. Indian J Nephrol. 35:8–20.
2025.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Utsu Y, Isono Y, Masuda SI, Arai H,
Shimoji S, Matsumoto R, Tsushima T, Tanaka K, Matsuo K, Kimeda C,
et al: Time-dependent recovery of renal impairment in patients with
newly diagnosed multiple myeloma. Ann Hematol. 104:573–579.
2025.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Dhakal B, Hari P, Chhabra S, Szabo A, Lum
LG, Glass DD, Park JH, Donato M, Siegel DS, Felizardo TC and Fowler
DH: Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201)
safely induces disease remissions in relapsed, refractory multiple
myeloma. J Immunother Cancer. 13(e010649)2025.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Abdi J and Redegeld F: Toll-like receptor
1/2 activation reduces immunoglobulin free light chain production
by multiple myeloma cells in the context of bone marrow stromal
cells and fibronectin. PLoS One. 20(e0310395)2025.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Martins Rodrigues F, Jasielec J, Perpich
M, Kim A, Moma L, Li Y, Storrs E, Wendl MC, Jayasinghe RG, Fiala M,
et al: Germline predisposition in multiple myeloma. iScience.
28(111620)2024.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yoon IC, Do N, Vazquez T, Elder DE, Steele
KT and Rosenbach M: Injection site reaction to teclistamab in a
patient with multiple myeloma. JAAD Case Rep. 56:48–50.
2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Jimeno Sandoval JC, Cantatore M, Meakin L,
Menghini T, Owen L, Doran I, Erskine M and Rossanese M: Treatment,
prognosis, and outcome of dogs treated for rectal plasmacytoma: A
multicentric retrospective study. J Am Vet Med Assoc. 263:1–8.
2025.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Fotiou D and Katodritou E: From biology to
clinical practice: The bone marrow microenvironment in multiple
myeloma. J Clin Med. 14(327)2025.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Li Y, Kuang L, Huang B, Liu J, Chen M, Li
X, Gu J, Yu T and Li J: Early identification of the
non-transplanted functional high-risk multiple myeloma: Insights
from a predictive nomogram. Biomedicines. 13(145)2025.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Bahrani E, Perkins IU and North JP:
Diagnosing calciphylaxis: A review with emphasis on histopathology.
Am J Dermatopathol. 42:471–480. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhou Y, Chen Y, Yin G and Xie Q:
Calciphylaxis and its co-occurrence with connective tissue
diseases. Int Wound J. 20:1316–1327. 2023.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hosler GA, Weibel L and Wang RC: The cause
of follicular spicules in multiple myeloma. JAMA Dermatol.
151:457–458. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Satta R, Casu G, Dore F, Longinotti M and
Cottoni F: Follicular spicules and multiple ulcers: Cutaneous
manifestations of multiple myeloma. J Am Acad Dermatol. 49:736–740.
2003.PubMed/NCBI View Article : Google Scholar
|
![Karyotype analysis revealing complex
chromosomal abnormalities in advanced MM. Conventional karyotyping
revealed multiple numerical and structural abnormalities (red
arrows) characteristic of high-risk MM: i) Hyperdiploidy with
tetraploid cells (83-85<4n>,XXY), including an additional X
chromosome. ii) Loss of Y chromosome (-Y), a common finding in
hematological malignancies. iii) High-level polysomy of chromosome
1 (+1,+1), totaling four copies, indicating aggressive disease. iv)
Dicentric chromosome [dic(1;10)(p13;q26)], suggesting genomic
instability. v) Pseudo-isodicentric chromosome [psu idic(1)(p21)], reflecting complex chromosomal
rearrangement. vi) Additional material on chromosomes 7 and 8
[add(7)(q32),add(8)(p23)x2]. vii) Possible unidentified
material on chromosome 17 [?add(17)(q22)x2]. ix) Monosomy of chromosomes
19, 20, 21 and 22 (green arrows). xi) One to two marker chromosomes
(+1-2mar). xii) Mosaic karyotype: Four abnormal clones with complex
karyotype and 16 normal male karyotypes (46,XY), consistent with
clonal evolution. MM, multiple myeloma.](/article_images/etm/30/3/etm-30-03-12930-g00.jpg)
